The Neurologist's Perspective

What Do We Know and Where Do We Go?

Aaron Miller, Dennis Bourdette, Paul Ritvo, William Stuart, Timothy Vollmer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The neurology panel reviewed the natural history of multiple sclerosis, therapy of acute exacerbations and chronic progressive disease, outcome measurement, and sexual dysfunction. A survey conducted among neurologists, both MS specialists and generalists, revealed widespread use of high dose pulse methylprednisolone therapy, prevalent use of oral corticosteroids, and anticipated acceptance of interferon 1 beta therapy. Studies confirm that MS is usually a progressive disease, with half of patients requiring gait assistance within fifteen years of onset, but the illness shortens mean life expectancy by only six to seven years. High dose intravenous corticosteroids or ACTH hasten recovery from acute attacks, but the effect of oral corticosteroids in moderate doses has been called into question by recent trials in isolated optic neuritis. In these studies, patients treated with oral prednisone had a higher frequency of relapse and a higher rate of conversion to clinical MS than did patients treated with high dose methylprednisolone. Improved outcome measurements are needed, as existing clinical scales have many deficiencies. Magnetic resonance imaging will probably find expanding use in clinical trials. At the “What Do We Know?” conference, preliminary plans were formulated to establish a research consortium, tentatively called the North American Research Consortium on Multiple Sclerosis (NARCOMS), to investigate clinical issues in MS. Despite evidence that sexual dysfunction is prevalent in MS, specific data, especially of a prospective nature, are insufficient. Therefore, the neurology panel proposed the development of an instrument to evaluate sexual function in MS longitudinally.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalNeurorehabilitation and Neural Repair
Volume8
Issue number3
DOIs
StatePublished - 1994

Fingerprint

Adrenal Cortex Hormones
Methylprednisolone
Neurology
Multiple Sclerosis
Optic Neuritis
Interferon-beta
Prednisone
Life Expectancy
Gait
Research
Adrenocorticotropic Hormone
Chronic Disease
Therapeutics
Magnetic Resonance Imaging
Clinical Trials
Recurrence
Neurologists
Surveys and Questionnaires

Keywords

  • Magnetic resonance imaging
  • Multiple sclerosis
  • Outcome
  • Sexual dysfunction
  • Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Rehabilitation

Cite this

The Neurologist's Perspective : What Do We Know and Where Do We Go? / Miller, Aaron; Bourdette, Dennis; Ritvo, Paul; Stuart, William; Vollmer, Timothy.

In: Neurorehabilitation and Neural Repair, Vol. 8, No. 3, 1994, p. 105-111.

Research output: Contribution to journalArticle

Miller, Aaron ; Bourdette, Dennis ; Ritvo, Paul ; Stuart, William ; Vollmer, Timothy. / The Neurologist's Perspective : What Do We Know and Where Do We Go?. In: Neurorehabilitation and Neural Repair. 1994 ; Vol. 8, No. 3. pp. 105-111.
@article{10f0362bdd7f496fb9c8a0b3c6e30b2b,
title = "The Neurologist's Perspective: What Do We Know and Where Do We Go?",
abstract = "The neurology panel reviewed the natural history of multiple sclerosis, therapy of acute exacerbations and chronic progressive disease, outcome measurement, and sexual dysfunction. A survey conducted among neurologists, both MS specialists and generalists, revealed widespread use of high dose pulse methylprednisolone therapy, prevalent use of oral corticosteroids, and anticipated acceptance of interferon 1 beta therapy. Studies confirm that MS is usually a progressive disease, with half of patients requiring gait assistance within fifteen years of onset, but the illness shortens mean life expectancy by only six to seven years. High dose intravenous corticosteroids or ACTH hasten recovery from acute attacks, but the effect of oral corticosteroids in moderate doses has been called into question by recent trials in isolated optic neuritis. In these studies, patients treated with oral prednisone had a higher frequency of relapse and a higher rate of conversion to clinical MS than did patients treated with high dose methylprednisolone. Improved outcome measurements are needed, as existing clinical scales have many deficiencies. Magnetic resonance imaging will probably find expanding use in clinical trials. At the “What Do We Know?” conference, preliminary plans were formulated to establish a research consortium, tentatively called the North American Research Consortium on Multiple Sclerosis (NARCOMS), to investigate clinical issues in MS. Despite evidence that sexual dysfunction is prevalent in MS, specific data, especially of a prospective nature, are insufficient. Therefore, the neurology panel proposed the development of an instrument to evaluate sexual function in MS longitudinally.",
keywords = "Magnetic resonance imaging, Multiple sclerosis, Outcome, Sexual dysfunction, Therapy",
author = "Aaron Miller and Dennis Bourdette and Paul Ritvo and William Stuart and Timothy Vollmer",
year = "1994",
doi = "10.1177/136140969400800303",
language = "English (US)",
volume = "8",
pages = "105--111",
journal = "Neurorehabilitation and Neural Repair",
issn = "1545-9683",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - The Neurologist's Perspective

T2 - What Do We Know and Where Do We Go?

AU - Miller, Aaron

AU - Bourdette, Dennis

AU - Ritvo, Paul

AU - Stuart, William

AU - Vollmer, Timothy

PY - 1994

Y1 - 1994

N2 - The neurology panel reviewed the natural history of multiple sclerosis, therapy of acute exacerbations and chronic progressive disease, outcome measurement, and sexual dysfunction. A survey conducted among neurologists, both MS specialists and generalists, revealed widespread use of high dose pulse methylprednisolone therapy, prevalent use of oral corticosteroids, and anticipated acceptance of interferon 1 beta therapy. Studies confirm that MS is usually a progressive disease, with half of patients requiring gait assistance within fifteen years of onset, but the illness shortens mean life expectancy by only six to seven years. High dose intravenous corticosteroids or ACTH hasten recovery from acute attacks, but the effect of oral corticosteroids in moderate doses has been called into question by recent trials in isolated optic neuritis. In these studies, patients treated with oral prednisone had a higher frequency of relapse and a higher rate of conversion to clinical MS than did patients treated with high dose methylprednisolone. Improved outcome measurements are needed, as existing clinical scales have many deficiencies. Magnetic resonance imaging will probably find expanding use in clinical trials. At the “What Do We Know?” conference, preliminary plans were formulated to establish a research consortium, tentatively called the North American Research Consortium on Multiple Sclerosis (NARCOMS), to investigate clinical issues in MS. Despite evidence that sexual dysfunction is prevalent in MS, specific data, especially of a prospective nature, are insufficient. Therefore, the neurology panel proposed the development of an instrument to evaluate sexual function in MS longitudinally.

AB - The neurology panel reviewed the natural history of multiple sclerosis, therapy of acute exacerbations and chronic progressive disease, outcome measurement, and sexual dysfunction. A survey conducted among neurologists, both MS specialists and generalists, revealed widespread use of high dose pulse methylprednisolone therapy, prevalent use of oral corticosteroids, and anticipated acceptance of interferon 1 beta therapy. Studies confirm that MS is usually a progressive disease, with half of patients requiring gait assistance within fifteen years of onset, but the illness shortens mean life expectancy by only six to seven years. High dose intravenous corticosteroids or ACTH hasten recovery from acute attacks, but the effect of oral corticosteroids in moderate doses has been called into question by recent trials in isolated optic neuritis. In these studies, patients treated with oral prednisone had a higher frequency of relapse and a higher rate of conversion to clinical MS than did patients treated with high dose methylprednisolone. Improved outcome measurements are needed, as existing clinical scales have many deficiencies. Magnetic resonance imaging will probably find expanding use in clinical trials. At the “What Do We Know?” conference, preliminary plans were formulated to establish a research consortium, tentatively called the North American Research Consortium on Multiple Sclerosis (NARCOMS), to investigate clinical issues in MS. Despite evidence that sexual dysfunction is prevalent in MS, specific data, especially of a prospective nature, are insufficient. Therefore, the neurology panel proposed the development of an instrument to evaluate sexual function in MS longitudinally.

KW - Magnetic resonance imaging

KW - Multiple sclerosis

KW - Outcome

KW - Sexual dysfunction

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84965533963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965533963&partnerID=8YFLogxK

U2 - 10.1177/136140969400800303

DO - 10.1177/136140969400800303

M3 - Article

VL - 8

SP - 105

EP - 111

JO - Neurorehabilitation and Neural Repair

JF - Neurorehabilitation and Neural Repair

SN - 1545-9683

IS - 3

ER -